Product Overview
The E. coli Residual RNA Detection Kit is designed for the quantitative detection of residual host cell RNA originating from E. coli expression systems across a variety of biopharmaceutical products — supporting a process-related impurity testing requirement relevant to recombinant protein and other E. coli-derived manufacturing workflows. The kit employs reverse transcription quantitative PCR (RT-qPCR) technology to perform rapid, specific, and reliable quantitative detection of residual E. coli RNA. By reverse-transcribing residual RNA into cDNA prior to quantitative PCR amplification, the assay provides sensitive detection suited to monitoring RNA clearance across in-process and final product samples, complementing residual DNA testing as part of a comprehensive host cell nucleic acid impurity monitoring strategy.
Components & Storage
| Reagent | Quantity | Storage |
| E. coli RNA Control | 50 μL × 1 tube | -20℃ |
| One Step qPCR Buffer | 500 μL × 2 tubes | -20℃protect form light |
| One Step Enzyme MIX | 100 μL × 1 tube | -20℃protect form light |
| E. coli RNA Primer&Probe MIX | 400 μL × 1 tube | -20℃protect form light |
| RNA IPC Primer&Probe MIX | 200 μL × 1 tube | -20℃protect form light |
| RNase-Free H2O | 1.2 mL × 3 tubes | -20℃ |
Product Features
- Specific RT-qPCR-based RNA quantitation: Combining reverse transcription with quantitative PCR, this kit specifically targets residual E. coli RNA, providing sensitive and reliable detection distinct from residual DNA testing methods.
- Rapid, reliable analytical workflow: The RT-qPCR format supports fast turnaround for quantitative results, enabling efficient integration into routine bioprocessing quality control and release testing schedules.
- Applicable across diverse biopharmaceutical product types: The kit is designed for use across a variety of biopharmaceutical products derived from E. coli expression systems, supporting consistent residual RNA monitoring throughout different manufacturing platforms and product formats.
FAQ
Q1: Why is residual host cell RNA monitored separately from residual host cell DNA?
Residual host cell RNA and DNA are distinct nucleic acid impurities with different chemical properties and clearance behaviors during downstream purification. While residual DNA testing is a well-established regulatory expectation, monitoring residual RNA provides additional characterization of host cell nucleic acid clearance, which can be relevant for certain product types or manufacturing platforms where comprehensive impurity profiling is required.
Q2: How does RT-qPCR enable detection of residual RNA, and how does this differ from standard DNA quantitation methods?
RT-qPCR first reverse-transcribes RNA into complementary DNA (cDNA) using a reverse transcriptase enzyme, after which the resulting cDNA is quantified via standard quantitative PCR. This reverse transcription step is what allows RNA-specific targets to be detected and quantified, distinguishing this assay from residual DNA quantitation kits that amplify genomic DNA sequences directly without a reverse transcription step.
Q3: What types of biopharmaceutical products is this kit suitable for testing?
This kit is designed for use across a variety of biopharmaceutical products manufactured using E. coli expression systems, including recombinant protein therapeutics and other E. coli-derived biologics, supporting residual RNA monitoring at relevant stages of the manufacturing and release testing process.